RFXANK Antibody

Western Blot: RFXANK Antibody [H00008625-B01P] - Analysis of RFXANK expression in transfected 293T cell line by RFXANK polyclonal antibody. Lane 1: RFXANK transfected lysate(26.07 KDa). Lane 2: Non-transfected lysate.

Product Discontinued

RFXANK Antibody Summary

• Description: Quality control test: Antibody reactive against mammalian transfected lysate.
• Immunogen: RFXANK (NP_604389.1, 1 a.a. - 237 a.a.) full-length human protein. MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSSPQGSSLKHSTTLTNRQRGNEVSALPATLDCDNLVNKPDERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYTDIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVALGYRKVQQVIENHILKLFQSNLVPADPE
• Isotype: IgG
• Clonality: Polyclonal
• Host: Mouse
• Gene: RFXANK
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Western Blot
• Application Notes: It has been used for WB and Functional.

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.4)
• Preservative: No Preservative
• Purity: Protein G purified

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for RFXANK Antibody

• ANKRA1Regulatory factor X subunit B
• ankyrin repeat-containing regulatory factor X-associated protein
• BLS
• DNA-binding protein RFXANK
• F14150_1
• MGC138628
• regulatory factor X-associated ankyrin-containing proteinAnkyrin repeat family A protein 1
• RFXB
• RFX-BRFX-Bdelta4

Background

RFX-B is the gene responsible for the bare lymphocyte syndrome (BLS) which is characterized by a lack of MHC class II transcription. Subsequently, there is a lack of B and T cell responses to foreign antigens. RFX-B is an MHC class II transcription factor that is defective in BLS.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: RFXANK
• Uniprot:
  • NP_604389.1(Human)